Enzon Pharma (ENZN) Ends Development of rhMBL, Announces Survivin Antagonist IND Accepted
Tweet Send to a Friend
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced the discontinuation of the current recombinant human Mannose-Binding Lectin (rhMBL) clinical program, as it did not meet the criteria established for its continued development.
Sepertaly, Enzon announced the FDA accepted the Company's Investigational New Drug (IND) application for the use of its Survivin antagonist. The Company will open a Phase I study evaluating safety of the Survivin antagonist during the first quarter of 2009.
Sepertaly, Enzon announced the FDA accepted the Company's Investigational New Drug (IND) application for the use of its Survivin antagonist. The Company will open a Phase I study evaluating safety of the Survivin antagonist during the first quarter of 2009.
You May Also Be Interested In
- Tesla (TSLA) Ramps Higher (GM)
- GlaxoSmithKline (GSK) Receives Bid for Thrombosis Brands, NDB Site
- AngioDynamics (ANGO) NanoKnife Receives IDE Approval from FDA
Create E-mail Alert Related Categories
FDA, Hot List
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
